1
|
Kobe A, Tselikas L, Deschamps F, Roux C, Delpla A, Varin E, Hakime A, de Baère T. Thermal ablation of ultrasound and non-contrast computed tomography invisible primary and secondary liver tumors: targeting by selective intra-arterial lipiodol injection. Diagn Interv Radiol 2023; 29:609-613. [PMID: 36992626 PMCID: PMC10679642 DOI: 10.4274/dir.2022.221317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Accepted: 04/04/2022] [Indexed: 01/15/2023]
Abstract
PURPOSE To evaluate the technical feasibility and outcomes of thermal ablation following selective intra-arterial lipiodol injection (SIALI) for targeting primary and secondary liver tumors invisible on ultrasound (US) and non-contrast computed tomography (CT). METHODS This retrospective study included 18 patients with 20 tumors (67% male, mean age 60.8 ± 12.1 years). The 20 tumors included 15 liver metastases and 5 hepatocellular carcinomas. All patients underwent single-session SIALI and subsequent CT-guided thermal ablation. The primary outcome was a technical success, defined as visualization of the tumor after SIALI and successful thermal ablation. Secondary outcomes were local recurrence rate and procedure-related complications. RESULTS The median tumor size was 1.5 (1-2.5) cm. In addition, SIALI was performed with a median volume of 3 (1-10) mL of lipiodol resulting in intra-tumoral iodized oil accumulation in 19 tumors and negative imprint with iodized oil accumulation of the surrounding liver parenchyma in 1 tumor. The technical success rate was 100%. No local occurrence was observed at a mean follow-up time of 3 ± 2.5 years. CONCLUSION SIALI to tag liver tumors not visible with US and non-contrast CT before percutaneous ablation is highly feasible and has a high success rate for the treatment of both primary and secondary liver tumors.
Collapse
Affiliation(s)
- Adrian Kobe
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| | - Lambros Tselikas
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| | - Frédéric Deschamps
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| | - Charles Roux
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| | - Alexandre Delpla
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| | - Eloi Varin
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| | - Antoine Hakime
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| | - Thierry de Baère
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, Villejuif, France
| |
Collapse
|
2
|
Kobe A, Deschamps F, Meyblum L, Varin E, Delpla A, Hakime A, Teriitehau C, Roux C, Boileve A, Gelli M, de Baère T, Tselikas L. Coil Embolization of Variant Hepatic Arteries During Percutaneous Arterial Port Catheter Placement for Intraarterial Chemotherapy: Analysis of Intrahepatic Perfusion Redistribution and Treatment Efficacy. Cardiovasc Intervent Radiol 2023; 46:69-79. [PMID: 36319713 DOI: 10.1007/s00270-022-03303-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 10/13/2022] [Indexed: 11/05/2022]
Abstract
PURPOSE The purpose of this study was to analyze the intrahepatic perfusion redistribution after embolization of hepatic arterial variants during percutaneous arterial port catheter placement as well as to investigate the treatment efficacy of intraarterial chemotherapy in perfusion redistribution-dependent compared to redistribution-independent liver areas. MATERIALS AND METHODS This retrospective study included 62 patients (67.7% males, mean age of 56 ± 12 years). A replaced left hepatic artery was encountered in 36/62 (58.1%), a replaced right hepatic artery in 19/62 (30.6%) and a replaced left and right hepatic artery in 7/62 of patients (11.3%), respectively. Subjective perfusion analysis was performed on digital subtracted angiography and computed tomography (CT)/cone-beam computed tomography (CBCT) images evaluating the visibility of the main, segmental and subsegmental branches of the embolized variant hepatic artery, re-perfused from intrahepatic arterial anastomoses. For objective perfusion analysis ROI measurements on CT/CBCT images were taken in the redistribution-dependent and redistribution-independent liver lobe. Response analysis according to RECIST 1.1 was separately calculated for the redistribution-dependent and redistribution-independent liver lobe. RESULTS Intrahepatic reperfusion of the embolized variant hepatic artery was observed immediately after embolization with visualization of the subsegmental branches in 95.2% of patients. ROI measurements on CT/CBCT images (right lobe mean 76 ± 30.2 HU, left lobe mean 74.4 ± 30.5, p-value 0.88) did not show any differences. Treatment response after intraarterial chemotherapy did not differ between the redistribution-dependent and redistribution-independent liver lobes. CONCLUSION Embolization of hepatic arterial variants during percutaneous arterial port catheter placement results in effective intrahepatic perfusion redistribution and does not compromise treatment efficacy of intraarterial chemotherapy in the redistribution-dependent liver lobe.
Collapse
Affiliation(s)
- Adrian Kobe
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
| | - Frédéric Deschamps
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Louis Meyblum
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Eloi Varin
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Alexandre Delpla
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Antoine Hakime
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Christophe Teriitehau
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Charles Roux
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Alice Boileve
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - Massimiliano Gelli
- Department of Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | - Thierry de Baère
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| | - Lambros Tselikas
- Department of Interventional Radiology, Gustave Roussy Cancer Center, 114 Rue Edouard Vaillant, 94805, Villejuif, France
| |
Collapse
|
3
|
Tselikas L, Dardenne A, de Baere T, Faron M, Ammari S, Farhane S, Suzzoni S, Danlos FX, Raoult T, Susini S, Al Shatti N, Mouraud S, Deschamps F, Kobe A, Delpla A, Roux C, Baldini C, Soria JC, Barlesi F, Massard C, Robert C, Champiat S, Marabelle A. Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients. Eur J Cancer 2022; 172:1-12. [PMID: 35724442 DOI: 10.1016/j.ejca.2022.05.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 05/10/2022] [Accepted: 05/13/2022] [Indexed: 11/24/2022]
Abstract
PURPOSE Many intratumoural (IT) immunotherapies are currently developed in the clinic with the aim of overcoming primary and secondary resistance and/or to limit on-target/off-tumour toxicities of immune checkpoint targeted therapies. This study aimed to describe the feasibility, safety and efficacy of IT immunotherapy treatments. DESIGN This retrospective single-centre study included the first 100 consecutive patients enrolled in Gustave Roussy's Human IntraTumoral-ImmunoTherapy (HIT-IT) program. Patient characteristics, target description, image guidance, safety and response according to iRECIST (Response Evaluation Criteria in Solid Tumours for immunotherapy trials) were recorded. Predictive factors of complications and responses were analysed. Survival was also reported. RESULTS From 09/2015 to 05/2020, 100 patients had 115 tumours injected during 423 treatment cycles. Most frequent primary tumour arose from the skin (n = 49), digestive track (n = 4) or head and neck (n = 8). Injected tumours' mean diameter was 37 ± 23 mm, and a median number of 4 IT injections per patient (interquartile range:3-5) were performed. Targeted tumours for IT injections were superficial lymph nodes (36.5%), subcutaneous lesions (25.2%), liver tumours (20.9%) and others (17.4% including tumour sites such as deep lymph nodes or lung). Most patients (72%) received systemic immunotherapy in combination with HIT-IT. Procedure- and drug-related adverse events (AEs) occurred in 11.3% and 33.3% of the treatment cycles, respectively. Only 3 procedure-related AEs were grade-3 (0.7%); and no grade-4 or 5 occurred. Among all cycles, 7 grade-3 and 1 grade-5 drug-related AEs were reported. Complete and partial responses were achieved for 5% and 18% of patients, respectively, while stable disease was the best response for 11%. Patients receiving HIT-IT as a 1st-line treatment (24%), or not previously pre-treated with immunotherapy (53%) responded better, p = 0.001 and p = 0.004, respectively. From 1st cycle of IT, 12-month overall progression-free survival and overall survival were 21% (14-31%) and 57% (47-68%), respectively. CONCLUSIONS This retrospective study, conducted on patients with cancer and treated within clinical trials at Gustave Roussy, demonstrates the feasibility and safety of the IT immunotherapy strategy.
Collapse
Affiliation(s)
- Lambros Tselikas
- Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France; Radiologie Interventionnelle, Gustave Roussy, Villejuif, France; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France; Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France.
| | - Antoine Dardenne
- Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
| | - Thierry de Baere
- Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France; Radiologie Interventionnelle, Gustave Roussy, Villejuif, France; Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France
| | - Matthieu Faron
- Oncostat U1018, INSERM, Paris-Saclay University, Labeled Ligue Contre le Cancer, Villejuif, France
| | - Samy Ammari
- Département de Radiologie, Gustave Roussy, Villejuif, France
| | - Siham Farhane
- Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France
| | - Steve Suzzoni
- Département Pharmacie, Gustave Roussy, Villejuif, France
| | - François-Xavier Danlos
- Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France; Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
| | - Thibault Raoult
- Service de Promotion des Essais Cliniques, Gustave Roussy, Villejuif, France
| | - Sandrine Susini
- Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France
| | - Nael Al Shatti
- Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France
| | - Severine Mouraud
- Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France
| | | | - Adrian Kobe
- Radiologie Interventionnelle, Gustave Roussy, Villejuif, France
| | | | - Charles Roux
- Radiologie Interventionnelle, Gustave Roussy, Villejuif, France
| | - Capucine Baldini
- Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
| | - Jean-Charles Soria
- Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France
| | - Fabrice Barlesi
- Département de Médecine Oncologique, Gustave Roussy, Villejuif, France; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
| | - Christophe Massard
- Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France; Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
| | - Caroline Robert
- Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France; Département de Médecine Oncologique, Gustave Roussy, Villejuif, France
| | - Stéphane Champiat
- Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France; Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
| | - Aurélien Marabelle
- Centre D'Investigation Clinique BIOTHERIS, INSERM CIC1428, Villejuif, France; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif, France; Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France; Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France
| |
Collapse
|
4
|
Kobe A, Tselikas L, Deschamps F, Roux C, Delpla A, Varin E, Hakime A, De Baère T. Single-session transarterial chemoembolization combined with percutaneous thermal ablation in liver metastases 3 cm or larger. Diagn Interv Imaging 2022; 103:516-523. [PMID: 35715327 DOI: 10.1016/j.diii.2022.05.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 05/23/2022] [Accepted: 05/27/2022] [Indexed: 11/03/2022]
Abstract
PURPOSE The purpose of this study was to evaluate the safety and efficacy of transarterial chemoembolization (TACE) combined with percutaneous thermal ablation in patients with liver metastases 3 cm in diameter or larger. MATERIALS AND METHODS This retrospective study included 39 patients with a total of 46 liver metastases treated. There were 14 men and 25 women, with a mean age of 55 ± 13.3 (SD) (age range: 28-77 years). All patients were treated with a combination of TACE and thermal ablation in a single session. Primary outcome was local tumor progression. Secondary outcomes were procedure related complications and systemic disease progression. RESULTS Mean tumor size was 3.6 ± 0.6 (SD) cm (range: 3-5 cm). Conventional TACE was performed in 32 liver metastases (32/46; 70%) and drug-eluting beads-TACE in 14 liver metastases (14/46; 30%) followed by radiofrequency ablation in 34 (34/46; 74%), microwave ablation in 11 (11/46; 24%) and cryoablation in one (1/46; 2%) metastasis. Four grade 2 (4/39; 10%) complications were observed. After a mean follow up of 31.9 ± 26.1 (SD) months (range: 2-113 months) overall local tumor progression rate was 15% (7/46). Local tumor progression rate at 12 months was 13% (6/46). Overall systemic disease progression was seen in 29 patients (29/39; 74%) with a systemic disease progression rate at 12 months of 59% (23/39). CONCLUSION Treatment of large liver metastases with TACE and thermal ablation in a single session is safe and achieves high local control rate.
Collapse
Affiliation(s)
- Adrian Kobe
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, 94805 Villejuif, France.
| | - Lambros Tselikas
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France
| | - Frédéric Deschamps
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France
| | - Charles Roux
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, 94805 Villejuif, France
| | - Alexandre Delpla
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, 94805 Villejuif, France
| | - Eloi Varin
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, 94805 Villejuif, France
| | - Antoine Hakime
- Centre Imagerie Medicale Bachaumont Paris Centre, 75002 Paris, France
| | - Thierry De Baère
- Department of Interventional Radiology, Gustave Roussy-Cancer Center, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France
| |
Collapse
|
5
|
Roux C, Boileve A, Faron M, Lamartina L, Delpla A, Tselikas L, Durand-Labrunie J, Hescot S, de Baere T, Hadoux J, Deschamps F, Baudin E. Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma. Cancers (Basel) 2022; 14:cancers14112730. [PMID: 35681708 PMCID: PMC9179919 DOI: 10.3390/cancers14112730] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 05/27/2022] [Accepted: 05/30/2022] [Indexed: 02/06/2023] Open
Abstract
Objective: The recommended first-line treatment for low-tumor-burden ACC (stage IVa ACC) not amenable to radical resection is mitotane in association with loco-regional treatments (LRs). The aim of this study was to determine the patient population that would benefit the most from LR. Materials and methods: This retrospective monocentric expert center chart review study was performed from 2008 to 2021 and included stage IVa patients (≤2 tumoral organs) treated with LR (either radiotherapy, surgery, or interventional radiology). The primary endpoint was disease control (DC). Correlations between DC, time to systemic chemotherapy (TTC), overall survival (OS), and tumor characteristics were analyzed using Kaplan−Meier survival analysis and Cox’s proportional hazards regression model for multivariate analysis. Results: Thirty-four women (57%) and 26 men with a median age of 48.1 years (IQR: 38.3−59.8) were included. One hundred and nine LRs were performed, with a median of 2 (IQR: 1−3) per patient. DC was achieved in 40 out of 60 patients (66.7%). Patients with DC had a significantly longer TTC (HR: 0.27, p < 0.001) and OS (HR: 0.22, p < 0.001). Patients with less than or equal to 5 metastases (HR: 6.15 (95% CI: 1.88−20.0), p = 0.002) or a maximum metastasis diameter below 3 cm had higher rates of DC (HR: 3.78 (95% CI: 1.09−13.14), p = 0.035). Conclusion: stage IVa ACC patients with ≤5 metastases or a maximum metastasis diameter below 3 cm had favorable responses to LR. We propose the name oligometastatic ACC for this subgroup of patients.
Collapse
Affiliation(s)
- Charles Roux
- Gustave Roussy, Département de Radiologie Interventionnelle, F-94805 Villejuif, France; (A.D.); (L.T.); (T.d.B.); (F.D.)
- Correspondence:
| | - Alice Boileve
- Gustave Roussy, Département D’oncologie Endocrinienne, F-94805 Villejuif, France; (A.B.); (L.L.); (J.H.); (E.B.)
| | - Matthieu Faron
- Gustave Roussy, Département de Chirurgie, F-94805 Villejuif, France;
| | - Livia Lamartina
- Gustave Roussy, Département D’oncologie Endocrinienne, F-94805 Villejuif, France; (A.B.); (L.L.); (J.H.); (E.B.)
| | - Alexandre Delpla
- Gustave Roussy, Département de Radiologie Interventionnelle, F-94805 Villejuif, France; (A.D.); (L.T.); (T.d.B.); (F.D.)
| | - Lambros Tselikas
- Gustave Roussy, Département de Radiologie Interventionnelle, F-94805 Villejuif, France; (A.D.); (L.T.); (T.d.B.); (F.D.)
| | | | - Segolène Hescot
- Institut Curie, Département de Médecine Oncologique, F-75005 Paris, France;
| | - Thierry de Baere
- Gustave Roussy, Département de Radiologie Interventionnelle, F-94805 Villejuif, France; (A.D.); (L.T.); (T.d.B.); (F.D.)
| | - Julien Hadoux
- Gustave Roussy, Département D’oncologie Endocrinienne, F-94805 Villejuif, France; (A.B.); (L.L.); (J.H.); (E.B.)
| | - Frederic Deschamps
- Gustave Roussy, Département de Radiologie Interventionnelle, F-94805 Villejuif, France; (A.D.); (L.T.); (T.d.B.); (F.D.)
| | - Eric Baudin
- Gustave Roussy, Département D’oncologie Endocrinienne, F-94805 Villejuif, France; (A.B.); (L.L.); (J.H.); (E.B.)
| |
Collapse
|
6
|
De Baere T, Tselikas L, Delpla A, Roux C, Varin E, Kobe A, Yevich S, Deschamps F. Thermal ablation in the management of oligometastatic colorectal cancer. Int J Hyperthermia 2022; 39:627-632. [PMID: 35477367 DOI: 10.1080/02656736.2021.1941311] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
PURPOSE To review available evidence on thermal ablation of oligometastatic colorectal cancer. METHODS Technical and cancer specific considerations for percutaneous image-guided thermal ablation of oligometastatic colorectal metastases in the liver and lung were reviewed. Ablation outcomes are compared to surgical and radiation therapy literature. RESULTS The application of thermal ablation varies widely based on tumor burden, technical expertise, and local cancer triage algorithms. Ablation can be performed in combination or in lieu of other cancer treatments. For surgically non-resectable liver metastases, a randomized trial has demonstrated the superiority of thermal ablation combined with chemotherapy compared to systemic chemotherapy alone in term of progression-free survival and overall survival (OS), with 5-, and 8-year OS of 43.1% and 35.9% in the combined arm vs. 30.3% and 8.9% in the chemotherapy alone arm. As ablation techniques and technology improve, the role of percutaneous thermal ablation may expand even into surgically resectable disease. Many of the prognostic factors for better OS after local treatment of lung metastases are the same for surgery and thermal ablation, including size and number of metastases, disease-free interval, complete resection/ablation, negative carcinoembryonic antigen, neoadjuvant chemotherapy, and controlled extra-pulmonary metastases. When matched for these factors, thermal ablation for lung and liver metastases appears to provide equivalent overall survival as surgery, in the range of 50% at 5 years. Thermal ablation has limitations that should be respected to optimize patient outcomes and minimize complications including targets that are well-visualized by image guidance, measure <3cm in diameter, and be located at least 3mm distance from prominent vasculature or major bronchi. CONCLUSIONS The routine incorporation of image-guided thermal ablation into the therapeutic armamentarium for the treatment of oligometastatic colorectal cancer can provide long survival and even cure.
Collapse
Affiliation(s)
- Thierry De Baere
- Departement d'anesthésie, de chirurgie, et de radiologie interventionnelle, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | - Lambros Tselikas
- Departement d'anesthésie, de chirurgie, et de radiologie interventionnelle, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | - Alexandre Delpla
- Departement d'anesthésie, de chirurgie, et de radiologie interventionnelle, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | - Charles Roux
- Departement d'anesthésie, de chirurgie, et de radiologie interventionnelle, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | - Eloi Varin
- Departement d'anesthésie, de chirurgie, et de radiologie interventionnelle, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | - Adrian Kobe
- Departement d'anesthésie, de chirurgie, et de radiologie interventionnelle, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| | - Steven Yevich
- Interventional Radiology Department, MD Anderson Cancer Center, Houston, TX, USA
| | - Frederic Deschamps
- Departement d'anesthésie, de chirurgie, et de radiologie interventionnelle, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, UFR Médecine Le Kremlin-Bicêtre, Le Kremlin Bicêtre, France
| |
Collapse
|
7
|
de Baere T, Roux C, Noel G, Delpla A, Deschamps F, Varin E, Tselikas L. Robotic assistance for percutaneous needle insertion in the kidney: preclinical proof on a swine animal model. Eur Radiol Exp 2022; 6:13. [PMID: 35257224 PMCID: PMC8901810 DOI: 10.1186/s41747-022-00265-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 01/17/2022] [Indexed: 01/04/2023] Open
Abstract
Abstract
Background
We evaluated the accuracy, safety, and feasibility of a computed tomography (CT)-guided robotic assistance system for percutaneous needle placement in the kidney.
Methods
Fiducials surgically implanted into the kidneys of two pigs were used as targets for subsequent robotically-assisted needle insertion. Robotically-assisted needle insertions and CT acquisitions were coordinated using respiratory monitoring. An initial scan volume data set was used for needle insertion planning defining skin entry and target point. Then, needle insertion was performed according to robot positioning. The accuracy of needle placement was evaluated upon the distance between the needle tip and the predefined target on a post needle insertion scan. A delayed contrast-enhanced CT scan was acquired to assess safety.
Results
Eight needle trajectories were performed with a median procedural time measured from turning on the robotic system to post needle insertion CT scan of 21 min (interquartile range 15.5−26.5 min). Blind review of needle placement accuracy was 2.3 ± 1.2 mm (mean ± standard deviation) in lateral deviation, 0.7 ± 1.7 mm in depth deviation, and 2.8 ± 1.3 mm in three-dimensional Euclidian deviation. All needles were inserted on the first attempt, which determined 100% feasibility, without needle readjustment. The angulation and length of the trajectory did not impact on the needle placement accuracy. Two minor procedure-related complications were encountered: 2 subcapsular haematomas (13 × 6 mm and 35 × 6 mm) in the same animal.
Conclusions
Robotically-assisted needle insertion was shown feasible, safe and accurate in a swine kidney model. Further larger studies are needed.
Collapse
|
8
|
Kobe A, Tselikas L, Deschamps F, Roux C, Delpla A, Varin E, Hakime A, de Baère T. Thermal Ablation Combined with Selective Transarterial Embolization of Centrally Located Renal Cell Carcinomas Measuring 3 cm or Larger. Cardiovasc Intervent Radiol 2022; 45:371-379. [DOI: 10.1007/s00270-021-03036-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 12/01/2021] [Indexed: 12/13/2022]
|
9
|
Roux C, Tselikas L, Delpla A, Yevich S, Teriitehau C, Hakime A, Varin E, Kobe A, de Baère T, Deschamps F. Percutaneous fixation of impending fracture of the hip. Tech Vasc Interv Radiol 2022; 25:100802. [DOI: 10.1016/j.tvir.2022.100802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
10
|
Najafi A, Al Ahmar M, Bonnet B, Delpla A, Kobe A, Madani K, Roux C, Deschamps F, de Baère T, Tselikas L. The PEARL Approach for CT-guided Lung Biopsy: Assessment of Complication Rate. Radiology 2021; 302:473-480. [PMID: 34726537 DOI: 10.1148/radiol.2021210360] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Background Percutaneous CT-guided biopsy of lung nodules is an established method with high diagnostic accuracy but a high rate of pneumothorax and chest tube insertion compared with endobronchial methods. Purpose To investigate the effect of a protocol combining patient positioning biopsy-side down, needle removal during expiration, autologous blood patch sealing, rapid rollover, and pleural patching (PEARL) on complication rate after percutaneous CT-guided lung biopsy, especially chest tube insertion. Materials and Methods In a secondary analysis of both prospectively and retrospectively acquired data from December 2019 to November 2020, consecutive participants underwent biopsy with use of the PEARL protocol (prospective data) and were compared with patients who underwent biopsy at the same tertiary cancer center according to the standard method without any additional techniques (controls, retrospective data). Patient demographics, lesion characteristics, intraprocedural data, complications, and histologic results were recorded and compared. Results One hundred patients in the control group (mean age ± standard deviation, 63 years ± 12; 61 men) and 100 participants in the PEARL group (mean age, 64 years ± 12; 48 men) were evaluated. No differences were found in patient and lesion characteristics. The emphysema rate was 47 of 100 patients (47%) in both groups. The rate of pneumothorax was 37 of 100 patients (37%) in the control group versus 16 of 100 (16%) in the PEARL group (P = .001). Of the pneumothoraxes that occurred, fewer were during the intervention in the PEARL group, with 21 of 37 onsets (57%) in the control group versus three of 16 onsets (19%) in the PEARL group (P < .001). A chest tube was inserted in 13 of 100 patients (13%) in the control group and only in one of 100 (1%) in the PEARL group (P = .002). Histologic findings were diagnostic in 94 of 100 patients (94%) in the control group and 95 of 100 (95%) in the PEARL group (P > .99). Conclusion During CT-guided percutaneous lung biopsy, a protocol of positioning biopsy-side down, needle removal during expiration, autologous blood patch sealing, rapid rollover, and pleural patching, or PEARL, reduced rates of pneumothorax and chest tube insertion. © RSNA, 2021.
Collapse
Affiliation(s)
- Arash Najafi
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Marc Al Ahmar
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Baptiste Bonnet
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Alexandre Delpla
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Adrian Kobe
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Khaled Madani
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Charles Roux
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Frédéric Deschamps
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Thierry de Baère
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| | - Lambros Tselikas
- From the Department of Interventional Radiology, Institut Gustave Roussy, Villejuif, Île-de France, France
| |
Collapse
|
11
|
Madani K, Najafi A, Boticella A, Roux C, Tselikas L, Delpla A, Al Ahmar M, de Baere T, Deschamps F. Combined local treatments for vertebral metastases with limited epidural extension. Support Care Cancer 2021; 30:337-345. [PMID: 34287688 DOI: 10.1007/s00520-021-06443-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2021] [Accepted: 07/13/2021] [Indexed: 12/22/2022]
Abstract
OBJECTIVES Vertebral metastases with limited epidural extension (VMLEE) are frequently encountered in cancer patients; they can cause severe and debilitating symptoms including pain and neurological impairment and are usually treated by radiotherapy. In this study, we mainly evaluated the safety of combined local treatments (CLT), associating radiofrequency ablation (RFA) with vertebroplasty and radiotherapy (RT) to treat VMLEE. Also, we aimed to evaluate the short-term efficacy of CLT on bone metastases palliation and long-term prevention of skeletal-related events. METHODS We retrospectively reviewed treatment complications, pain palliation, and skeletal complications after combined local treatments (CLT) for vertebral metastasis with limited epidural extension (VMLEE). RESULTS Eighteen consecutive patients had CLT for 24 VMLEE, between June 2016 and January 2021. No major post-treatment complication was recorded. Nine patients had pain before the initiation of CLT. One month after CLT, only 3 patients had residual pain with a significant decrease of visual analogue scale (VAS), from 7.3 ± 2.4 to 2 ± 0 (p = .008), as well as the mean morphine milligram equivalent dose from 196.6 ± 135.7 to 38.5 ± 26, p = .008. Mean follow-up was 16.7 ± 11.5 months. Only one vertebra showed an increase of a preexisting vertebral fracture. Nine VMLEE had evidence of residual disease, including 2 which resulted in spinal cord compression (2, 11 months). CONCLUSION CLT was safe and effective for pain palliation and long-term prevention of skeletal-related events for treatment of patients with VMLEE. The effectiveness of this combined treatment on tumor control and epidural involvement on the long term needs further investigation.
Collapse
Affiliation(s)
- Khaled Madani
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France.
| | - Arash Najafi
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France
| | - Angela Boticella
- Department of Radiation Therapy, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France
| | - Charles Roux
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France
| | - Lambros Tselikas
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France
| | - Alexandre Delpla
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France
| | - Marc Al Ahmar
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France
| | - Thierry de Baere
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France
| | - Frédéric Deschamps
- Department of Interventional Radiology, Gustave Roussy Cancer Campus, 114 Rue Édouard Vaillant, 94800, Villejuif, France.
| |
Collapse
|
12
|
Prud'homme C, Teriitehau C, Adam J, Kyaw Tun J, Roux C, Hakime A, Delpla A, Deschamps F, de Baere T, Tselikas L. Lung microwave ablation - an in vivo swine tumor model experiment to evaluate ablation zones. Int J Hyperthermia 2021; 37:879-886. [PMID: 32689829 DOI: 10.1080/02656736.2020.1787530] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
PURPOSE To evaluate microwave ablation (MWA) algorithms, comparing pulsed and continuous mode in an in vivo lung tumor mimic model. MATERIALS AND METHODS A total of 43 lung tumor-mimic models of 1, 2 or 3 cm were created in 11 pigs through an intra-pulmonary injection of contrast-enriched minced muscle. Tumors were ablated under fluoroscopic and 3D-CBCT-guidance using a single microwave antenna. Continuous (CM) and pulsed mode (PM) were used. According to tumor size, 3 different algorithms for both continuous and pulsed mode were used. The ablation zones were measured using post-procedural 3D-CBCT and on pathologic specimens. RESULTS Two radiologists measured the ablation zones on CBCT and they significantly correlated with macroscopic and microscopic pathological findings: r = 0.75 and 0.74 respectively (p < 0.0001) (inter-observer correlation r = 0.9). For 1, 2 and 3 cm tumors mimics lesions (TMLs), mean maximal and transverse ablation diameters were 3.6 [Formula: see text] 0.3 × 2.2 [Formula: see text] 0.3 cm; 4.1 [Formula: see text] 0.5 × 2.6 [Formula: see text] 0.3 cm and 4.8 [Formula: see text] 0.3 × 3.2 [Formula: see text] 0.3 cm respectively using CM; And, 3.0 [Formula: see text] 0.2 × 2.1 [Formula: see text] 0.2 cm; 4.0 [Formula: see text] 0.4 × 2.7 [Formula: see text] 0.4 cm and 4.6 [Formula: see text] 0.4 × 3.2 [Formula: see text] 0.4 cm respectively for PM, without any significant difference except for 1 cm TMLs treated by PM ablation which were significantly smaller (p = 0.009) The sphericity index was 1.6, 1.6, 1.5 and 1.4, 1.5, 1.4 at 1, 2 and 3 cm for CM and PM respectively, p = 0.07, 0.14 and 0.13 for 1, 2 and 3 cm tumors mimics. CONCLUSION Microwave ablation for 1-3 cm lung tumors were successfully realized but with a moderate reproducibility rate, using either CM or PM. Immediate post ablation CBCT can accurately evaluate ablation zones.
Collapse
Affiliation(s)
- Clara Prud'homme
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France
| | - Christophe Teriitehau
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France
| | - Julien Adam
- Department of Pathology, Gustave Roussy, Villejuif, France
| | - Jimmy Kyaw Tun
- Interventional Radiology Department, Barts Health NHS Trust, London, UK
| | - Charles Roux
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France
| | - Antoine Hakime
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France
| | - Alexandre Delpla
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France
| | - Fréderic Deschamps
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France
| | - Thierry de Baere
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France.,Université Paris-Saclay, Saint-Aubin, France
| | - Lambros Tselikas
- Département d' Anesthésie, Chirurgie et Interventionel, Gustave Roussy, Villejuif, France
| |
Collapse
|
13
|
Assouline J, Tselikas L, Roux C, Yevich S, Delpla A, Najafi A, Al Ahmar M, Bijot JC, de Baère T, Deschamps F. Prophylactic Percutaneous Consolidation of Large Osteolytic Tumors of the Pelvic Ring Using Fixation by Internal Cemented Screws. Radiol Imaging Cancer 2021; 3:e200137. [PMID: 33988476 DOI: 10.1148/rycan.2021200137] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Purpose To evaluate the efficacy, durability, and safety of percutaneous fixation by internal cemented screw (FICS) for prophylactic consolidation of impending pathologic fractures of the pelvic ring. Materials and Methods In this single-institute retrospective study, patients with large, minimally symptomatic to asymptomatic osteolytic tumors of the pelvic ring that were treated with percutaneous cone-beam CT-guided FICS procedures were included (January 2014 to May 2019). Follow-up cross-section imaging and clinical reports were reviewed for procedural complications and assessment of the long-term consolidation efficacy on the basis of the development of pathologic fracture or need for additional surgical intervention. All continuous variables were expressed as a mean with standard deviation, and dichotomous variables were expressed as frequencies and percentages. Results Fifty consecutive patients (mean age, 60 years ± 12; 27 men) underwent prophylactic FICS for consolidation of 54 osteolytic tumors (mean size, 51 mm ± 21.5; range, 30-114 mm). Local tumor destruction was performed in association with FICS in 38 patients (76%) using percutaneous thermal and/or radiation therapy. Follow-up exceeded a year in 35 patients (70%), with mean follow-up of 22 months ± 18 (range, 1-67 months). Long-term consolidation efficacy was 98% (49 of 50), with the development of a pathologic fracture in only one patient 20 months after FICS. Procedural complications were limited to two patients with self-resolving hematoma, one patient with inflammatory sciatic pain, and one patient with focal pain at the ischial tuberosity. Conclusion Percutaneous FICS provides a safe and durable minimally invasive treatment for the prevention of pathologic fractures of the pelvic ring. Keywords: Interventional-MSK, Percutaneous, Skeletal-Axial, Metastases, Oncology Supplemental material is available for this article. © RSNA, 2020.
Collapse
Affiliation(s)
- Jessica Assouline
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Lambros Tselikas
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Charles Roux
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Steven Yevich
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Alexandre Delpla
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Arash Najafi
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Marc Al Ahmar
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Jean-Charles Bijot
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Thierry de Baère
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| | - Frédéric Deschamps
- From the Department of Interventional Radiology, Gustave Roussy-Cancer Center, 114 Rue Edouard Vaillant, 94805 Villejuif, France (J.A., L.T., C.R., S.Y., A.D., A.N., M.A.A., J.C.B., T.d.B., F.D.); Laboratory of Translational Research in Immunology (LRTI), INSERM U1015, Villejuif France (L.T.); and University Paris-Sud Le Kremlin Bicêtre, France (L.T., T.d.B., F.D.)
| |
Collapse
|
14
|
Najafi A, de Baere T, Purenne E, Bayar A, Al Ahmar M, Delpla A, Roux C, Madani K, Assouline J, Deschamps F, Tselikas L. Risk factors for local tumor progression after RFA of pulmonary metastases: a matched case-control study. Eur Radiol 2021; 31:5361-5369. [PMID: 33474569 DOI: 10.1007/s00330-020-07675-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 11/22/2020] [Accepted: 12/28/2020] [Indexed: 12/31/2022]
Abstract
OBJECTIVES Curative treatment of oligometastatic pulmonary disease aims at eradication of all metastases. Radiofrequency ablation (RFA) has been shown to be an efficient method and the frequency of local tumor progression (LTP) should be minimized. The objective of this study was to determine the morphological and treatment-related risk factors for LTP after RFA of pulmonary metastases. MATERIALS AND METHODS All patients treated with RFA for pulmonary metastases from 2002 to 2014 were reviewed. All LTPs from 2011 to 2014 were individually matched on the basis of tumor size, number, and histology. In total, 48 LTPs and 112 controls were blindly analyzed for morphological factors including vicinity of bronchus and vessels as well as treatment-related factors such as the size of the ablation zone and ablation margins. RESULTS In the simple regression analysis, the significant predictive variables were ≤ 5-mm distance to a large bronchus (OR = 4.94; p = 0.0095) or large vessel (OR = 7.09; p < 0.001), minimal ablation margin (≤ 5 mm (OR = 42.67; p < 0.001), and a central-peripheral ablation offset/ablation zone size > 0.36 (OR = 13.83; p = 0.013). In the multiple regression model, only a minimal ablation margin ≤ 5 mm remained a significant risk factor for LTP. CONCLUSION Only the minimal ablation margin remains significant in the multiple regression analysis; the other factors are presumably surrogates of an insufficient ablation margin. Improvement of lung RFA outcomes can probably be obtained by immediate post RFA evaluation of ablation margins to ensure a minimal ablation margin of at least 5 mm. KEY POINTS • A distance < 5 mm to a bronchus or vessel of over 3 mm diameter is associated with insufficient ablation margin and thus risk factors for local tumor progression after pulmonary radiofrequency ablation. • A minimal ablation margin of > 5 mm after pulmonary RFA is associated with significantly less local tumor progression and should be looked for at the end of treatment session before needle removal in order to decrease local tumor progression. • Tumor location, pleural contact, occurrence of intra-alveolar hemorrhage, pulmonary atelectasis, and pneumothorax are not associated with an increased risk of local tumor progression.
Collapse
Affiliation(s)
- Arash Najafi
- Kantonsspital Winterthur, Brauerstrasse 15, 8401, Winterthur, Switzerland. .,Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
| | - Thierry de Baere
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Edouard Purenne
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Amine Bayar
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Marc Al Ahmar
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Alexandre Delpla
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Charles Roux
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Khaled Madani
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Jessica Assouline
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Frederic Deschamps
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - Lambros Tselikas
- Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| |
Collapse
|
15
|
Tselikas L, Champiat S, Sheth RA, Yevich S, Ammari S, Deschamps F, Farhane S, Roux C, Susini S, Mouraud S, Delpla A, Raoult T, Robert C, Massard C, Barlesi F, Soria JC, Marabelle A, de Baere T. Interventional Radiology for Local Immunotherapy in Oncology. Clin Cancer Res 2021; 27:2698-2705. [PMID: 33419781 DOI: 10.1158/1078-0432.ccr-19-4073] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 10/24/2020] [Accepted: 01/04/2021] [Indexed: 11/16/2022]
Abstract
Human intratumoral immunotherapy (HIT-IT) is under rapid development, with promising preliminary results and high expectations for current phase III trials. While outcomes remain paramount for patients and the referring oncologists, the technical aspects of drug injection are critical to the interventional radiologist to ensure optimal and reproducible outcomes. The technical considerations for HIT-IT affect the safety, efficacy, and further development of this treatment option. Image-guided access to the tumor allows the therapeutic index of a treatment to be enhanced by increasing the intratumoral drug concentration while minimizing its systemic exposure and associated on-target off-tumor adverse events. Direct access to the tumor also enables the acquisition of cancer tissue for sequential sampling to better understand the pharmacodynamics of the injected immunotherapy and its efficacy through correlation of immune responses, pathologic responses, and imaging tumor response. The aim of this article is to share the technical insights of HIT-IT, with particular consideration for patient selection, lesion assessment, image guidance, and technical injection options. In addition, the organization of a standard patient workflow is discussed, so as to optimize HIT-IT outcome and the patient experience.
Collapse
Affiliation(s)
- Lambros Tselikas
- Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Gustave Roussy, Villejuif, France. .,Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Gustave Roussy, Villejuif, France
| | - Stephane Champiat
- Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France
| | - Rahul A Sheth
- Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Steve Yevich
- Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Samy Ammari
- Radiology Department, Gustave Roussy, Université Paris Saclay, Villejuif, France
| | - Frederic Deschamps
- Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Gustave Roussy, Villejuif, France
| | - Siham Farhane
- Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France
| | - Charles Roux
- Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Gustave Roussy, Villejuif, France
| | - Sandrine Susini
- Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Gustave Roussy, Villejuif, France
| | - Severine Mouraud
- Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Gustave Roussy, Villejuif, France
| | - Alexandre Delpla
- Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Gustave Roussy, Villejuif, France
| | - Thibault Raoult
- Service de Promotion des Etudes Cliniques (SPEC), Gustave Roussy, Université Paris Saclay, Villejuif, France
| | - Caroline Robert
- Department of Cancer Medicine, Gustave Roussy, Villejuif, France.,Gustave Roussy Cancer Campus, Université Paris Saclay, Saint-Aubin, France
| | - Christophe Massard
- Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.,Gustave Roussy Cancer Campus, Université Paris Saclay, Saint-Aubin, France
| | - Fabrice Barlesi
- Gustave Roussy Cancer Campus, Université Paris Saclay, Saint-Aubin, France
| | - Jean-Charles Soria
- Gustave Roussy Cancer Campus, Université Paris Saclay, Saint-Aubin, France
| | - Aurélien Marabelle
- Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Gustave Roussy, Villejuif, France.,Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France
| | - Thierry de Baere
- Département d'Anesthésie, Chirurgie et Interventionnel (DACI), Gustave Roussy, Villejuif, France.,Gustave Roussy Cancer Campus, Université Paris Saclay, Saint-Aubin, France
| |
Collapse
|
16
|
Dassa M, Roux C, Tselikas L, Delpla A, Yevich S, Faron M, Teriitehau C, Hakime A, Al Ahmar M, de Baère T, Deschamps F. Image-guided Percutaneous Fixation with Internal Cemented Screws of Impending Femoral Neck Pathologic Fractures in Patients with Metastatic Cancer: Safety, Efficacy, and Durability. Radiology 2020; 297:721-729. [DOI: 10.1148/radiol.2020201341] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
17
|
Tselikas L, Garzelli L, Mercier O, Auperin A, Lamrani L, Deschamps F, Yevich S, Roux C, Mussot S, Delpla A, Varin F, Hakime A, Teriitehau C, Le Péchoux C, Pradère P, Caramella C, Besse B, Fadel E, de Baere T. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. Diagn Interv Imaging 2020; 102:19-26. [PMID: 33020025 DOI: 10.1016/j.diii.2020.09.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Revised: 08/13/2020] [Accepted: 09/01/2020] [Indexed: 12/14/2022]
Abstract
PURPOSE The purpose of this study was to compare efficacy and tolerance between radiofrequency ablation (RFA) and surgery for the treatment of oligometastatic lung disease. MATERIALS AND METHODS This retrospective study reviewed patients treated in two institutions for up to 5 pulmonary metastases with a maximal diameter of 4cm and without associated pleural involvement or thoracic lymphadenopathy. Patient demographics, tumor characteristics, treatment outcome, and length of hospital stay were compared between the two groups. Efficacy endpoints were overall survival (OS), progression-free survival (PFS) and pulmonary or local tumor progression rates. RESULTS Among 204 patients identified, 78 patients (42 men, 36 women; mean age, 53.3±14.9 [SD]; age range: 15-81 years) were treated surgically, while 126 patients (59 men, 67 women; mean age, 62.2±10.8 [SD]; age range: 33-80 years) were treated by RFA. In the RFA cohort, patients were significantly older (P<0.0001), with more extra-thoracic localisation (P=0.015) and bilateral tumour burden (P=0.0014). In comparison between surgery and RFA cohorts, respectively, the 1- and 3-year OS were 94.8 and 67.2% vs. 94 and 72.1% (P=0.46), the 1- and 3-year PFS were 49.4% and 26.1% vs. 38.9% and 14.8% (P=0.12), the pulmonary progression rates were 39.1% and 56% vs. 41.2% and 65.3% (P>0.99), and the local tumour progression rates were 5.4% and 10.6% vs. 4.8% and 18.6% (P=0.07). Tumour size>2cm was associated with a significantly higher local tumor progression in the RFA group (P=0.010). Hospitalisation stay was significantly shorter in the RFA group (median of 3 days; IQR=2 days; range: 2-12 days) than in the surgery group (median of 9 days; IQR=2 days; range: 6-21 days) (P<0.01). CONCLUSION RFA should be considered a minimally-invasive alternative with similar OS and PFS to surgery in the treatment of solitary or multiple lung metastases measuring less than 4cm in diameter without associated pleural involvement or thoracic lymphadenopathy.
Collapse
Affiliation(s)
- L Tselikas
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France.
| | - L Garzelli
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - O Mercier
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - A Auperin
- Biostatistics and Epidemiology Unit, Gustave-Roussy INSERM 1018, 94805 Villejuif, France
| | - L Lamrani
- Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - F Deschamps
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - S Yevich
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; Interventional Radiology, MD-Anderson, 77030 Houston, TX, USA
| | - C Roux
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - S Mussot
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - A Delpla
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - F Varin
- Department of Anesthesiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - A Hakime
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - C Teriitehau
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - C Le Péchoux
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Radiation Therapy, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - P Pradère
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - C Caramella
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Radiology Department, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - B Besse
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Cancer Medicine, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - E Fadel
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - T de Baere
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France
| |
Collapse
|
18
|
Moulin B, Tselikas L, Gravel G, Al Ahmar M, Delpla A, Yevich S, Hakime A, Territehau C, De Baere T, Deschamps F. Safety and Efficacy of Multilevel Thoracolumbar Vertebroplasty in the Simultaneous Treatment of Six or More Pathologic Compression Fractures. J Vasc Interv Radiol 2020; 31:1683-1689.e1. [PMID: 32921566 DOI: 10.1016/j.jvir.2020.03.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Revised: 02/14/2020] [Accepted: 03/03/2020] [Indexed: 11/30/2022] Open
Abstract
PURPOSE To assess the safety and efficacy of multilevel thoracolumbar vertebroplasty in the simultaneous treatment of ≥ 6 painful pathologic compression fractures. MATERIALS AND METHODS Retrospective review was conducted of 50 consecutive patients treated with vertebroplasty for ≥ 6 pathologic compression fractures in a single session for pain palliation at a tertiary single cancer center from 2015 to 2019. Outcomes measured included procedural safety according to Common Terminology Criteria for Adverse Events (CTCAE), change in 4-week postprocedure back pain by numeric rating scale (NRS), comparison of daily opioid medication consumption, and development of skeletal-related events. RESULTS A total of 397 pathologic compression fractures were treated during 50 sessions (mean, 7.9 per patient ± 1.5). Mean procedure duration was 162 minutes ± 35, mean postoperative hospitalization duration was 1.6 days ± 0.9, and mean follow-up duration was 401 days ± 297. Seven complications were recorded, including 1 case of symptomatic polymethyl methacrylate pulmonary embolism. No major complications (CTCAE grade 4/5) were reported. NRS pain score was significantly decreased (5.0 ± 1.8 vs 1.7 ± 1.4; P < .0001), with a mean score decrease of 3.3 points (66%). Opioid agent use decreased significantly (76 mg/24 h ± 42 vs 45 mg/24 h ± 37; P = .0003), with a mean decrease of 30 mg/24 h (39%). Skeletal-related events occurred in 7 patients (14%). CONCLUSIONS Multilevel vertebroplasty for ≥ 6 pathologic compression fractures is safe and provides significant palliative benefit when performed simultaneously.
Collapse
Affiliation(s)
- Benjamin Moulin
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France.
| | - Lambros Tselikas
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France; Université Paris-Sud, Le Kremlin Bicêtre, France
| | - Guillaume Gravel
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France
| | - Marc Al Ahmar
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France
| | - Alexandre Delpla
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France
| | - Steven Yevich
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France
| | - Antoine Hakime
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France
| | - Christophe Territehau
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France
| | - Thierry De Baere
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France; Université Paris-Sud, Le Kremlin Bicêtre, France
| | - Fréderic Deschamps
- Interventional Radiology Unit and Imaging Department and Anesthesiology Unit, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif 94805, France; Université Paris-Sud, Le Kremlin Bicêtre, France
| |
Collapse
|
19
|
Abstract
Interventional oncology and the value of thermal ablation of small tumors is increasingly recognized by the oncological community. Primary lung cancers and lung metastases have been one of the most researched applications of percutaneous ablation and as interventional oncologists gain more experience and confidence, it is becoming a more effective treatment with expanding indications. Importantly, the current literature does not demonstrate major differences in survival between ablation, sublobar resection, and stereotactic body radiation. The advantages of percutaneous ablation over other local therapies like surgery or SBRT are significantly lower morbidity, mortality, and repeatability of treatments. The focus of this essay is to highlight technical and procedural aspects of lung ablation as well as management and follow-up in a practical fashion.
Collapse
|
20
|
Moulin B, Delpla A, Tselikas L, Al Ahmar M, Prud'homme C, Roux C, Yevich S, Laurent S, Hakime A, Territehau C, Gravel G, De Baere T, Deschamps F. Multi-Level Vertebroplasty for 6 or More Painful Osteoporotic Vertebral Body Compression Fractures Performed in the Same Procedural Setting: A Safety and Efficacy Report in Cancer Patients. Cardiovasc Intervent Radiol 2020; 43:1041-1048. [PMID: 32382857 DOI: 10.1007/s00270-020-02480-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Accepted: 04/04/2020] [Indexed: 10/24/2022]
Abstract
PURPOSE To assess safety and efficacy of multi-level vertebroplasty, when treating 6 or more levels in the same procedural setting for the management of osteoporotic vertebral compression fractures (oVCF) in cancer patients. MATERIALS AND METHODS Single institution retrospective review from 2015 to 2019 of patients treated for multi-level oVCF in a single session procedural setting by vertebroplasty of 6 or more levels. Procedure outcomes collected included procedural complications, pre- and 4 week post-procedure pain score by numeric rating scale, opioid usage, and vertebral height changes. RESULTS In total, 197 vertebral levels were treated in 24 procedures (mean 8.2 ± 1.8 levels). Mean procedure duration was 167 + / - 41 min, and mean postoperative hospitalization duration was 2.1 + / - 1.9 days. Four grade I or II complications occurred according to CIRSE classification. Two patients had a symptomatic pulmonary cement embolism; although there was no statistical difference between pre- and postoperative mean blood saturation (95.9 + / - 1.7% and 94.8 + / - 2.0%, respectively, p = 0.066). Pain score significantly improved after treatment (6.5 ± 1.3 vs 3.2 + / - 1.4, p < 0.0001) with a mean decrease of 3.3 (51%). Post-procedure daily opioid use also significantly improved (mean 35.8 + / - 36.8 mg/24 h vs 18.5 + / - 27.8 mg/24 h, p = 0.0089), with a mean decrease of 17.3 mg/24 h (48%). Refracture was found in 2 of 105 levels treated (1.9%), and no difference was found in thoraco-lumbar height and angulation. Five patients experienced new painful fractures at a non-treated level. CONCLUSION Multi-level vertebroplasty for 6 or more levels is a safe and effective treatment for the management of multi-level oVCF in cancer patients.
Collapse
Affiliation(s)
- Benjamin Moulin
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France.
| | - Alexandre Delpla
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Lambros Tselikas
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France.,Université Paris-Sud, Le Kremlin Bicêtre, France
| | - Marc Al Ahmar
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Clara Prud'homme
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Charles Roux
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Steven Yevich
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Sophie Laurent
- Pain Management Unit, Institut Gustave Roussy, Villejuif, Paris, France
| | - Antoine Hakime
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Christophe Territehau
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Guillaume Gravel
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
| | - Thierry De Baere
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France.,Université Paris-Sud, Le Kremlin Bicêtre, France
| | - Fréderic Deschamps
- Department Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France.,Université Paris-Sud, Le Kremlin Bicêtre, France
| |
Collapse
|
21
|
Delpla A, Tselikas L, De Baere T, Laurent S, Mezaib K, Barat M, Nguimbous O, Prudhomme C, Al Ahmar M, Moulin B, Deschamps F. Correction to: Preventive Vertebroplasty for Long-Term Consolidation of Vertebral Metastases. Cardiovasc Intervent Radiol 2020; 43:807. [DOI: 10.1007/s00270-020-02445-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
22
|
Barat M, Tselikas L, de Baère T, Gravel G, Yevich S, Delpla A, Magand N, Louvel G, Hadoux J, Berdelou A, Terroir M, Baudin E, Schlumberger M, Leboulleux S, Deschamps F. Corrigendum to "Thermal-ablation of vertebral metastases prevents adverse events in patients with differentiated thyroid carcinoma" [Eur. J. Radiol. 119 (2019) 108650]. Eur J Radiol 2019; 121:108693. [PMID: 31594669 DOI: 10.1016/j.ejrad.2019.108693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M Barat
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
| | - L Tselikas
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - T de Baère
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - G Gravel
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - S Yevich
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - A Delpla
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - N Magand
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - G Louvel
- Department of Radiotherapy, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| | - J Hadoux
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - A Berdelou
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - M Terroir
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - E Baudin
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - M Schlumberger
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - S Leboulleux
- Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France
| | - F Deschamps
- Department of Interventional Radiology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
| |
Collapse
|
23
|
Delpla A, Tselikas L, De Baere T, Laurent S, Mezaib K, Barat M, Nguimbous O, Prudhomme C, Al-Hamar M, Moulin B, Deschamps F. Preventive Vertebroplasty for Long-Term Consolidation of Vertebral Metastases. Cardiovasc Intervent Radiol 2019; 42:1726-1737. [PMID: 31444627 DOI: 10.1007/s00270-019-02314-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2019] [Accepted: 08/16/2019] [Indexed: 12/13/2022]
Abstract
INTRODUCTION To evaluate the long-term consolidation of vertebral metastases (VM) after preventive vertebroplasty (PV) and to report risk factors of pathological fracture despite PV. MATERIALS AND METHODS Files of 100 consecutives cancer patients referred for PV of VM were retrospectively analyzed. We enumerated 215 VM at the time of the PV procedure (T0): 138 VM were considered at risk of pathological fracture and had PV (treated-VM), and 77 VM were not cemented. We compared the VM characteristics using the spine instability neoplastic score (SINS) at T0 and the rate of pathologic fracture between treated-VM and untreated-VM using Kaplan-Meier method. We analyzed risk factors of pathological fracture despite PV using treated-VM characteristics and quality of cement injection criteria. RESULTS Despite a lower SINS value at T0 (p < 0.001), the rate of pathological fracture was significantly higher among untreated-VM compared to the treated-VM, (log-rank, p < 0.001). Major risk factors of fracture among treated-VM were: SINS value ≥ 8 (p < 0.012), mechanical pain (p = 0.001), osteolytic lesion (p = 0.033), metastatic vertebral body involvement > 50% with no collapse (p < 0.001) and unilateral posterior involvement by the vertebral metastasis (p = 0.024), Saliou score < 9 (p = 0.008), vertebral metastasis filling with cement < 50% (p = 0.007) and the absence of cement's contact with vertebral endplates (p = 0.014). CONCLUSION PV is long-term effective for consolidation of VM and must be discussed at the early diagnosed. Quality of cement injection matters, suggesting that techniques that improve the quantity and the quality of cement diffusion into the VM must be developed.
Collapse
Affiliation(s)
- Alexandre Delpla
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France.
- Paris-Sud, Le Kremlin Bicêtre, France.
| | - Lambros Tselikas
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Thierry De Baere
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Sophie Laurent
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Karima Mezaib
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Maxime Barat
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Olivia Nguimbous
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Clara Prudhomme
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Marc Al-Hamar
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Benjamin Moulin
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| | - Frederic Deschamps
- Interventional Radiology Unit, Imaging Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, 94805, Villejuif, France
- Paris-Sud, Le Kremlin Bicêtre, France
| |
Collapse
|